+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

North America Dystonia Drugs Market Size, Share & Industry Trends Analysis Report By Distribution Channel, By Route of Administration, By Type, By Country and Growth Forecast, 2022 - 2028

  • PDF Icon

    Report

  • 70 Pages
  • February 2023
  • Region: North America
  • Marqual IT Solutions Pvt. Ltd (KBV Research)
  • ID: 5752591
The North America Dystonia Drugs Market should witness market growth of 4.8% CAGR during the forecast period (2022-2028).

Dystonia is classified according to three primary factors: the age at which symptoms manifest, the affected body regions, and the underlying reason. The likelihood that several body parts will be affected by dystonia is often proportional to the age of onset. The younger one is at the outset of symptoms, the greater the likelihood they may spread. In contrast, the greater the period in the beginning, the greater the likelihood that the disease will remain mild.

The neck (cervical dystonia or spasmodic torticollis), eyes (blepharospasm), jaw/mouth/lower face (oromandibular dystonia), vocal cords (laryngeal dystonia), or arms/legs might be affected by focal dystonia (limb dystonia). Other less common types of focal dystonias might involve abnormal stretching, bending, or twisting of the trunk (truncal dystonia), persistent contractions, and involuntary abdominal wall writhing (abdominal wall dystonia). Focal dystonia affects persons in their 40s and 50s more frequently and is commonly referred to as adult-onset dystonia. Around three times more women are impacted than men. Focal dystonias are typically classed as primary (idiopathic) and are not inherited.

The American healthcare system is a hub for innovation that creates and widely disseminates cutting-edge, life-improving therapies and provides healthcare consumers with a wide range of options. There are many advantages to the existing healthcare system. Also, the government is working on many areas where improvements may be made to lower prices, broaden access, raise quality, and improve Americans' health. HHS (Health and Human Services)aims to safeguard and provide accessible, high-quality healthcare equitably. The Department's activities are concentrated on lowering costs, enhancing the quality of healthcare services, assuring access to safe medical devices and medications, and expanding choice, affordability, and enrollment in high-quality healthcare coverage.

The US market dominated the North America Dystonia Drugs Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $317 Million by 2028. The Canada market is poised to grow at a CAGR of 6.8% during (2022-2028). Additionally, The Mexico market should witness a CAGR of 6.5% during (2022-2028).

Based on Distribution Channel, the market is segmented into Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers. Based on Route of Administration, the market is segmented into Oral and Injectable. Based on Type, the market is segmented into GABAergic Agents, Dopaminergic Agents, Anticonvulsants Drugs and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Pfizer, Inc., Novartis AG, Teva Pharmaceuticals Industries Ltd., AbbVie, Inc., F. Hoffmann-La Roche Ltd., Ipsen Pharma Biotech SAS, Hameln Pharma Gmbh (Siegfried Group, LLP), Amneal Pharmaceuticals, Inc., Merz Pharma GmbH & Co. KGaA, and Wellona Pharma.

Scope of the Study

By Distribution Channel

  • Drug Stores & Retail Pharmacies
  • Hospital Pharmacies
  • Online Providers

By Route of Administration

  • Oral
  • Injectable

By Type

  • GABAergic Agents
  • Dopaminergic Agents
  • Anticonvulsants Drugs
  • Others

By Country

  • US
  • Canada
  • Mexico
  • Rest of North America

Key Market Players

List of Companies Profiled in the Report:

  • Pfizer, Inc.
  • Novartis AG
  • Teva Pharmaceuticals Industries Ltd.
  • AbbVie, Inc.
  • F.Hoffmann-La Roche Ltd.
  • Ipsen Pharma Biotech SAS
  • Hameln Pharma Gmbh (Siegfried Group, LLP)
  • Amneal Pharmaceuticals, Inc.
  • Merz Pharma GmbH & Co. KGaA
  • Wellona Pharma

Unique Offerings

  • Exhaustive coverage
  • The highest number of Market tables and figures
  • Subscription-based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Dystonia Drugs Market, by Distribution Channel
1.4.2 North America Dystonia Drugs Market, by Route of Administration
1.4.3 North America Dystonia Drugs Market, by Type
1.4.4 North America Dystonia Drugs Market, by Country
1.5 Methodology for the research

Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market composition & scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints

Chapter 3. North America Dystonia Drugs Market by Distribution Channel
3.1 North America Drug Stores & Retail Pharmacies Market by Country
3.2 North America Hospital Pharmacies Market by Country
3.3 North America Online Providers Market by Country

Chapter 4. North America Dystonia Drugs Market by Route of Administration
4.1 North America Oral Market by Country
4.2 North America Injectable Market by Country

Chapter 5. North America Dystonia Drugs Market by Type
5.1 North America GABAergic Agents Market by Country
5.2 North America Dopaminergic Agents Market by Country
5.3 North America Anticonvulsants Drugs Market by Country
5.4 North America Others Market by Country

Chapter 6. North America Dystonia Drugs Market by Country
6.1 US Dystonia Drugs Market
6.1.1 US Dystonia Drugs Market by Distribution Channel
6.1.2 US Dystonia Drugs Market by Route of Administration
6.1.3 US Dystonia Drugs Market by Type
6.2 Canada Dystonia Drugs Market
6.2.1 Canada Dystonia Drugs Market by Distribution Channel
6.2.2 Canada Dystonia Drugs Market by Route of Administration
6.2.3 Canada Dystonia Drugs Market by Type
6.3 Mexico Dystonia Drugs Market
6.3.1 Mexico Dystonia Drugs Market by Distribution Channel
6.3.2 Mexico Dystonia Drugs Market by Route of Administration
6.3.3 Mexico Dystonia Drugs Market by Type
6.4 Rest of North America Dystonia Drugs Market
6.4.1 Rest of North America Dystonia Drugs Market by Distribution Channel
6.4.2 Rest of North America Dystonia Drugs Market by Route of Administration
6.4.3 Rest of North America Dystonia Drugs Market by Type

Chapter 7. Company Profiles
7.1 Pfizer, Inc.
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Regional & Segmental Analysis
7.1.4 Research & Development Expense
7.2 Novartis AG
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Segmental and Regional Analysis
7.2.4 Research & Development Expense
7.3 Teva Pharmaceutical Industries Ltd.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Regional Analysis
7.3.4 Research & Development Expenses
7.3.5 Recent strategies and developments:
7.3.5.1 Product Launches and Product Expansions:
7.4 AbbVie, Inc.
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Regional Analysis
7.4.4 Research & Development Expense
7.5 F. Hoffmann-La Roche Ltd.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expense
7.6 Ipsen Pharma Biotech SAS
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Segmental and Regional Analysis
7.6.4 Research & Development Expense
7.7 Hameln Pharma Gmbh (Siegfried Group, LLP)
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Research & Development Expenses
7.8 Amneal Pharmaceuticals, Inc.
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Segmental Analysis
7.8.4 Research & Development Expenses
7.9 Merz Pharma GmbH & Co. KGaA
7.9.1 Company Overview
7.9.2 Recent strategies and developments:
7.9.2.1 Approvals and Trials:
7.10. Wellona Pharma
7.10.1 Company Overview

Companies Mentioned

  • Pfizer, Inc.
  • Novartis AG
  • Teva Pharmaceuticals Industries Ltd.
  • AbbVie, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Ipsen Pharma Biotech SAS
  • Hameln Pharma Gmbh (Siegfried Group, LLP)
  • Amneal Pharmaceuticals, Inc.
  • Merz Pharma GmbH & Co. KGaA
  • Wellona Pharma

Methodology

Loading
LOADING...